TC BioPharm has appointed administrators, who have launched a sale process for the business and its assets.

TC BioPharm is an early developer of allogeneic Gamma-Delta T-Cell therapies, initially pioneering their use for the treatment of Acute Myeloid Leukemia (AML). It was the first to conduct phase two clinical studies in AML using Gamma-Delta T Cells.

The company operates from a research and development facility in Motherwell, with a small team of employees - none of whom will be immediately made redundant, as a sale is sought.

Joint administrator Michael Magnay said: “TC BioPharm is a pioneering, clinical-stage cell therapy company with an experienced and highly skilled team.

“Our priority is to run a sale process at pace, and we encourage any parties interested in acquiring the bu

See Full Page